Cardiac rhabdomyoma

disease
On this page

Also known as cardiac rhabdomyoma (disease)heart rhabdomyomarhabdomyoma of heartrhabdomyoma of the heart

Summary

Cardiac rhabdomyoma (MONDO:0006123) is a disease with 1 cohort gene and 1 clinical trial.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 1
  • Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecardiac rhabdomyoma
Mondo IDMONDO:0006123
EFOEFO:1000150
NCITC6739
UMLSC1332852
MedGen232027
GARD0027742
Anatomy (UBERON)UBERON:0000948
Is cancer (heuristic)no

Also known as: cardiac rhabdomyoma · cardiac rhabdomyoma (disease) · heart rhabdomyoma · rhabdomyoma of heart · rhabdomyoma of the heart

Data availability: 1 ClinVar variant · 1 HPO phenotype.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmbenign neoplasmcardiovascular organ benign neoplasm › benign neoplasm of heart › cardiac rhabdomyoma

Related subtypes (4): heart lipoma, benign neoplasm of endocardium, benign neoplasm of epicardium, benign neoplasm of myocardium

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
48943NM_000368.5(TSC1):c.2356C>T (p.Arg786Ter)TSC1Pathogeniccriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
TSC1Orphanet:210159Adult hepatocellular carcinoma
TSC1Orphanet:269008Isolated focal cortical dysplasia type IIb
TSC1Orphanet:538Lymphangioleiomyomatosis
TSC1Orphanet:805Tuberous sclerosis complex

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TSC1HGNC:12362ENSG00000165699Q92574Hamartinclinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TSC1HamartinNon-catalytic component of the TSC-TBC complex, a multiprotein complex that acts as a negative regulator of the canonical mTORC1 complex, an evolutionarily conserved central nutrient sensor that stimulates anabolic reactions and macromolec…

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TSC1Other/UnknownnoHamartin

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
gluteal muscle1
lateral globus pallidus1
substantia nigra pars compacta1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TSC1297ubiquitousmarkersubstantia nigra pars compacta, gluteal muscle, lateral globus pallidus

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
TSC15,445

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
TSC1Q925745

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 5. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Inhibition of TSC complex formation by AKT (PKB)12284.0×0.002TSC1
Energy dependent regulation of mTOR by LKB1-AMPK1393.8×0.006TSC1
TBC/RABGAPs1259.6×0.006TSC1
TP53 Regulates Metabolic Genes1129.8×0.009TSC1
Macroautophagy1115.3×0.009TSC1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
memory T cell differentiation15617.3×0.004TSC1
cellular response to decreased oxygen levels14213.0×0.004TSC1
negative regulation of ATP-dependent activity11685.2×0.004TSC1
negative regulation of cell size11685.2×0.004TSC1
regulation of cell-matrix adhesion11296.3×0.004TSC1
negative regulation of macroautophagy11123.5×0.004TSC1
regulation of stress fiber assembly1991.3×0.004TSC1
obsolete D-glucose import1842.6×0.004TSC1
activation of GTPase activity1732.7×0.004TSC1
cardiac muscle cell differentiation1674.1×0.004TSC1
positive regulation of focal adhesion assembly1648.1×0.004TSC1
negative regulation of TOR signaling1561.7×0.005TSC1
associative learning1481.5×0.005TSC1
cell projection organization1374.5×0.006TSC1
negative regulation of TORC1 signaling1324.1×0.006TSC1
adult locomotory behavior1300.9×0.006TSC1
synapse organization1280.9×0.006TSC1
myelination1251.5×0.007TSC1
hippocampus development1230.8×0.007TSC1
response to insulin1230.8×0.007TSC1
cerebral cortex development1205.5×0.007TSC1
cellular response to starvation1193.7×0.007TSC1
potassium ion transport1191.5×0.007TSC1
neural tube closure1187.2×0.007TSC1
cell-matrix adhesion1163.6×0.008TSC1
kidney development1140.4×0.008TSC1
cell population proliferation1102.8×0.011TSC1
adaptive immune response184.3×0.013TSC1
regulation of cell cycle174.6×0.014TSC1
protein stabilization166.9×0.015TSC1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
TSC100

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1TSC1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
TSC10

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02654340Not specifiedTERMINATEDBiomarkers for Tuberous Sclerosis Complex (BioTuScCom)